New drug offers promising path for rectal cancer treatment without surgery

The drug 'dostarlimab', known commercially as 'Jemperli', has generated significant medical interest after showing promising results in treating a specific type of locally advanced rectal cancer. The FDA has approved the drug as a precise treatment option for these cases.

According to media reports, the treatment targets patients with a specific mismatch repair deficiency, a genetic mutation that contributes to cancer cell growth and affects 5 to 10% of rectal cancer patients.

A study involving 154 patients showed that 68% of participants achieved a complete clinical response one year after treatment. Dr. Andrea Cercek, the study's lead researcher, noted that patients not only achieved this response but maintained it for extended periods, raising hopes for long-term efficacy.

Jemperli functions via immunotherapy, helping the body's natural defenses identify and attack cancer cells, potentially offering an alternative that could spare some patients from traditional surgery or chemotherapy.